» Articles » PMID: 35774603

Extract and Its Bioactive Component Cinnamaldehyde Show Anti-Tumor Effects Inhibition of Multiple Cellular Pathways

Overview
Journal Front Pharmacol
Date 2022 Jul 1
PMID 35774603
Authors
Affiliations
Soon will be listed here.
Abstract

is a tropical plant with traditional medicinal significance that possesses antimicrobial, antifungal, anti-parasitic, and anti-tumor properties. Here, we have elucidated the anti-tumor effects of extract (CZE) and its bioactive compound cinnamaldehyde (CIN) on oral cancer and elucidated underlying molecular mechanisms. Anti-tumor activities of CZE and CIN were demonstrated by various experiments on oral cancer cells (SCC-4, SCC-9, SCC-25). The cell proliferation, growth, cell cycle arrest, apoptosis, and autophagy were analyzed by MTT, clonogenic assay, propidium iodide, annexin-V-PI, DAPI, and acridine orange staining, respectively. The binding affinity of CIN towards dihydrofolate reductase and p38-MAP kinase alpha was analyzed by molecular docking. Western blot assay was performed to assess the alteration in the expression of various proteins. CZE and CIN treatment significantly inhibited the growth and proliferation of oral cancer cells in a dose-dependent manner. These treatments further induced apoptosis, cell cycle arrest, and autophagy. CZE and CIN inhibited the invasion and cytoplasmic translocation of NF-κB in these cell lines. CIN showed a high affinity to MAP kinase P38 alpha and dihydrofolate reductase with binding affinities of -6.8 and -5.9 kcal/mol, respectively. The cancer cells showed a decreased expression of various PI3k-AKT-mTOR pathways related to VEGF, COX-2, Bcl-2, NF-κB, and proteins post-treatment.

Citing Articles

Evaluation of different drying methods on the quality of barks by analytic hierarchy process method.

Li L, Chen L, Pan D, Zhu Y, Huang R, Chen J Heliyon. 2024; 10(14):e34608.

PMID: 39114071 PMC: 11305288. DOI: 10.1016/j.heliyon.2024.e34608.


The role and mechanism of cinnamaldehyde in cancer.

Peng J, Song X, Yu W, Pan Y, Zhang Y, Jian H J Food Drug Anal. 2024; 32(2):140-154.

PMID: 38934689 PMC: 11210466. DOI: 10.38212/2224-6614.3502.


Advances in pharmacological effects and mechanism of action of cinnamaldehyde.

Guo J, Yan S, Jiang X, Su Z, Zhang F, Xie J Front Pharmacol. 2024; 15:1365949.

PMID: 38903995 PMC: 11187351. DOI: 10.3389/fphar.2024.1365949.


Integrated transcriptomics and metabolomics analysis provides insights into aromatic volatiles formation in Cinnamomum cassia bark at different harvesting times.

Yao S, Tan X, Huang D, Li L, Chen J, Ming R BMC Plant Biol. 2024; 24(1):84.

PMID: 38308239 PMC: 10835945. DOI: 10.1186/s12870-024-04754-w.


A Comprehensive Review of Natural Products as Therapeutic or Chemopreventive Agents against Head and Neck Squamous Cell Carcinoma Cells Using Preclinical Models.

Liew Y, Karen-Ng L, Vincent-Chong V Biomedicines. 2023; 11(9).

PMID: 37760799 PMC: 10525836. DOI: 10.3390/biomedicines11092359.


References
1.
Gharat S, Momin M, Bhavsar C . Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Crit Rev Ther Drug Carrier Syst. 2016; 33(4):363-400. DOI: 10.1615/CritRevTherDrugCarrierSyst.2016016272. View

2.
Anjum F, Mohammad T, Almalki A, Akhtar O, Abdullaev B, Hassan M . Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase. OMICS. 2021; 25(9):580-590. DOI: 10.1089/omi.2021.0107. View

3.
Azevedo R, van Zeeland M, Raaijmakers H, Kazemier B, de Vlieg J, Oubrie A . X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors. Acta Crystallogr D Biol Crystallogr. 2012; 68(Pt 8):1041-50. DOI: 10.1107/S090744491201997X. View

4.
Aggarwal S, Sharma S, Das S . Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clin Chim Acta. 2015; 442:13-21. DOI: 10.1016/j.cca.2014.12.038. View

5.
Hennessy B, Smith D, Ram P, Lu Y, Mills G . Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004. DOI: 10.1038/nrd1902. View